{
    "Orphapacket": {
        "ORPHApacketId": "98841",
        "creationDate": "2024-07-01 09:48:26",
        "version": "1.3.29 / 4.1.7 [2023-08-02] (orientdb version)",
        "copyright": "Orphanet (c) 2024",
        "ORPHAcode": "98841",
        "Label": "Anaplastic large cell lymphoma",
        "PURL": "http://www.orpha.net/ORDO/Orphanet_98841",
        "DisorderType": {
            "value": "Disease",
            "PURL": "http://www.orpha.net/ORDO/Orphanet_377788"
        },
        "Synonyms": [
            {
                "Synonym": "ALCL"
            },
            {
                "Synonym": "CD30 positive anaplastic large cell lymphoma"
            },
            {
                "Synonym": "Ki-1 positive anaplastic large cell lymphoma"
            },
            {
                "Synonym": "Primary systemic ALCL"
            },
            {
                "Synonym": "sACL"
            }
        ],
        "TextSection": {
            "TextSectionType": "Definition",
            "Contents": "A rare and aggressive peripheral T-cell non-Hodgkin lymphoma belonging to the group of CD30-positive lymphoproliferative disorders which affects lymph nodes and extranodal sites. It is comprised of two sub-types based on the expression of a protein called anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL."
        },
        "Parents": [
            {
                "Parent": [
                    {
                        "ORPHAcode": "171918",
                        "Label": "T-cell non-Hodgkin lymphoma"
                    }
                ]
            },
            {
                "Parent": [
                    {
                        "ORPHAcode": "602675",
                        "Label": "Pediatric T-cell non-Hodgkin lymphoma"
                    }
                ]
            }
        ],
        "Childs": [],
        "Prevalences": {
            "Prevalence": [
                {
                    "Source": "European Medicines Agency 2011[INST]",
                    "PrevalenceType": "Point prevalence",
                    "PrevalenceQualification": "Value and class",
                    "PrevalenceClass": "1-9 / 100 000",
                    "ValMoy": "2.0",
                    "PrevalenceGeographic": "Europe"
                }
            ]
        },
        "AverageAgeOfOnsets": {
            "AverageAgeOfOnset": [
                {
                    "value": "All ages"
                }
            ]
        },
        "TypeOfInheritances": {
            "TypeOfInheritance": [
                {
                    "value": "Not applicable"
                }
            ]
        }
    }
}